Michael Löw
YOU?
Author Swipe
View article: Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma
Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma Open
Introduction: Multiple myeloma (MM) with t(11;14), present in approximately 16-24% of patients with MM, represents a unique disease subset with distinct features. BCL2 inhibition has shown efficacy in this subgroup; however, no BCL2-target…
View article: Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)
Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) Open
Introduction: Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) in combination with bortezomib (V) and dexamethasone (d). We investigated whether low-dose S combined with lenalidomide (R) wa…
View article: Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins Open
BH3 mimetic drugs that selectively target the pro-survival BCL2 proteins are highly promising for cancer treatment, most notably for treating blood cancers. Venetoclax, which inhibits BCL2, is now approved for treating chronic lymphocytic …
View article: Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach Open
Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach…
View article: Bilateral adrenal hemorrhage in a postpartum woman with multiple thromboemboli: A case report
Bilateral adrenal hemorrhage in a postpartum woman with multiple thromboemboli: A case report Open
Background Bilateral adrenal hemorrhage is a rare but often a fatal cause of primary adrenal insufficiency that can result in adrenal crisis if not identified and managed appropriately. Case presentation We present a case of a 27-year-old …
View article: Indolent T Cell Lymphoproliferation of the Gastrointestinal Tract: An Evolving Disease Entity
Indolent T Cell Lymphoproliferation of the Gastrointestinal Tract: An Evolving Disease Entity Open
Background: Indolent T cell lymphoproliferation of the gastrointestinal tract is a novel entity recently added to the 2016 WHO classification of lymphoid neoplasms. Classically, these patients demonstrate an immunophenotype consistent with…
View article: The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR) Open
The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real‐world…
View article: Low mortality in vaccinated immunocompromised haematology patients infected with <scp>SARS‐CoV</scp>‐2
Low mortality in vaccinated immunocompromised haematology patients infected with <span>SARS‐CoV</span>‐2 Open
Coronavirus disease 2019 (COVID‐19) infection in patients with haematological neoplasms has been associated with increased mortality; however, many studies in this patient group were reported early in the pandemic. The authors evaluated ou…
View article: Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study
Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study Open
Background: Carfilzomib (CFZ) is a next-generation proteasome inhibitor currently approved in combination with lenalidomide and dexamethasone (KRd) or with dexamethasone alone (Kd) for treatment of multiple myeloma (MM) patients with ≥1 pr…
View article: P1609: VERY LOW MORTALITY IN DOUBLE VACCINATED IMMUNOCOMPROMISED HAEMATOLOGY PATIENTS INFECTED WITH SARS-COV-2.
P1609: VERY LOW MORTALITY IN DOUBLE VACCINATED IMMUNOCOMPROMISED HAEMATOLOGY PATIENTS INFECTED WITH SARS-COV-2. Open
Background: Patients with immunocompromising haematological neoplasms (HN) are reported to be at high risk of death from SARS-CoV-2 (COVID19). However, many studies were conducted prior to widespread immunisation and availability of effect…
View article: COVID‐19 unmasks the critical role of primary healthcare providers in the timely diagnosis of multiple myeloma
COVID‐19 unmasks the critical role of primary healthcare providers in the timely diagnosis of multiple myeloma Open
View article: Infiltration of bone marrow space with chondromas mimicking progression of polycythemia vera
Infiltration of bone marrow space with chondromas mimicking progression of polycythemia vera Open
View article: Concomitant diagnosis of chronic myeloid leukaemia and myeloma
Concomitant diagnosis of chronic myeloid leukaemia and myeloma Open
View article: Rare case of diffuse large B-cell lymphoma presenting with central pontine myelinolysis
Rare case of diffuse large B-cell lymphoma presenting with central pontine myelinolysis Open
Central pontine myelinolysis (CPM) is commonly associated with osmotic stress and rapid correction of hyponatraemia. It has rarely been reported in conjunction with malignancies. We report a case where CPM was not only associated with a ne…
View article: Targeted Therapies for Multiple Myeloma
Targeted Therapies for Multiple Myeloma Open
Multiple myeloma continues to be a challenging disorder to treat despite improved therapies and the widespread use of proteasome inhibitors and immunomodulatory drugs. Although patient outcomes have improved, the disease continues to invar…
View article: Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
Spheroacanthocytes secondary to novel tyrosine kinase inhibitors Open
A 64-year-old male with ALK-positive nonsmall cell lung carcinoma on oral therapy with alectinib presented with pleural effusion. Full blood examination revealed hemoglobin of 90 g/L, white blood cell count 12.4 × 109/L, and platelet count…
View article: An Erg-driven transcriptional program controls B cell lymphopoiesis
An Erg-driven transcriptional program controls B cell lymphopoiesis Open
View article: Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells Open
View article: An Erg driven transcriptional program controls B-lymphopoiesis
An Erg driven transcriptional program controls B-lymphopoiesis Open
Summary/Abstract B-cell development is initiated by the stepwise differentiation of hematopoietic stem cells into lineage committed progenitors, ultimately generating the mature B-cells that mediate protective immunity. This highly regulat…
View article: IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis
IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis Open
The transcription factor interferon regulatory factor 4 (IRF4) is critical for the development, maintenance, and function of plasma cells. The mechanism by which IRF4 exerts its action in mature plasma cells has been elusive due to the dea…
View article: Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency Open
View article: IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos Open
Recent studies have demonstrated that the immunomodulatory drugs (IMiDs) lead to the degradation of the transcription factors Ikaros and Aiolos. However, why their loss subsequently leads to multiple myeloma (MM) cell death remains unclear…
View article: Lyn, Lupus, and (B) Lymphocytes, a Lesson on the Critical Balance of Kinase Signaling in Immunity
Lyn, Lupus, and (B) Lymphocytes, a Lesson on the Critical Balance of Kinase Signaling in Immunity Open
Systemic lupus erythematosus (SLE) is a progressive autoimmune disease characterized by increased sensitivity to self-antigens, auto-antibody production, and systemic inflammation. B cells have been implicated in disease progression and as…
View article: The functional role of interferon regulatory factor 4 in plasma cells
The functional role of interferon regulatory factor 4 in plasma cells Open
View article: Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma
Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma Open
The introduction of the novel agents has changed the treatment landscape of multiple myeloma (MM), with immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI) becoming the cornerstone of current therapy. Although triplet induction r…
View article: Periorbital papules as a presenting sign in multiple myeloma with AL amyloidosis
Periorbital papules as a presenting sign in multiple myeloma with AL amyloidosis Open
A 67-year-old woman of Indian heritage with no significant medical history presented with a 9-month history of progressive periorbital lesions consisting of coalescing pigmented papules (figure 1A). On systems review she reported concurren…
View article: Daily iron supplementation for improving anaemia, iron status and health in menstruating women
Daily iron supplementation for improving anaemia, iron status and health in menstruating women Open
Daily iron supplementation effectively reduces the prevalence of anaemia and iron deficiency, raises haemoglobin and iron stores, improves exercise performance and reduces symptomatic fatigue. These benefits come at the expense of increase…
View article: Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia
Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia Open
Cytogenetically normal acute myeloid leukemia (CN-AML) is heterogeneous and requires individualized prognostication. In spite of molecular characterization of CN-AML, many patients lack a clear indication for or against allogeneic stem cel…
View article: Efficacy and Safety of Daily Iron Supplementation in Children: Lessons from Three Systematic Reviews and Meta-analyses of Randomized Controlled Trials
Efficacy and Safety of Daily Iron Supplementation in Children: Lessons from Three Systematic Reviews and Meta-analyses of Randomized Controlled Trials Open
Objectives: 47% of pre-school children and 25% of school-aged children are anaemic.Daily iron supplementation remains a key anaemia control intervention, but benefits and safety in children are debated.We systematically reviewed evidence f…
View article: Effects of Daily Iron Supplementation on Physical Performance in Women of Reproductive Age: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Effects of Daily Iron Supplementation on Physical Performance in Women of Reproductive Age: A Systematic Review and Meta-analysis of Randomized Controlled Trials Open